At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 7, 2026 at 06:50 ET
ANI Pharmaceuticals announced the publication of NEW DAY clinical trial results for ILUVIEN in the journal Ophthalmology, reinforcing clinical data for its use in diabetic macular edema (DME). This is a scientific validation rather than a new clinical or commercial development.
- Results from the NEW DAY Phase 4 trial of ILUVIEN for diabetic macular edema were published in Ophthalmology, a peer-reviewed journal.
- The trial results were previously disclosed in July 2025; this press release highlights peer-reviewed publication.
- ILUVIEN is indicated for DME patients previously treated with corticosteroids without significant intraocular pressure rise.
- Safety data show high incidence of cataract (82%), intraocular pressure elevation (34% had ≥10 mm Hg increase), and need for IOP-lowering treatment (38%).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access